Using qHTS we identified the combination of HSP90 and PI3K inhibitors as one of the most efficacious drug therapies in ACC and validated the efficacy in vitro and in vivo using ACC PDOs and xenografts, respectively. The gene discussed is PIK3CB; the disease is adrenal cortex carcinoma.